Cargando…

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present many clinical features secreting peptides and neuroamines that cause distinct clinical syndromes such as carcinoid syndrome. However most of them are clinically silent until late presentation with mass effects. Surg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldelli, Roberto, Barnabei, A., Rizza, L., Isidori, A. M., Rota, F., Di Giacinto, P., Paoloni, A., Torino, F., Corsello, S. M., Lenzi, A., Appetecchia, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916777/ https://www.ncbi.nlm.nih.gov/pubmed/24570674 http://dx.doi.org/10.3389/fendo.2014.00007

Ejemplares similares

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors
por: Sansone, Andrea, et al.
Publicado: (2019)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study
por: Barnabei, Agnese, et al.
Publicado: (2018)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature
por: Appetecchia, Marialuisa, et al.
Publicado: (2014)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy
por: Crabtree, Judy S.
Publicado: (2017)

Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor
por: Song, Lili, et al.
Publicado: (2022)

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
por: Zanini, Sara, et al.
Publicado: (2020)

Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms
por: Yao, Hailing, et al.
Publicado: (2023)

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
por: Liverani, Chiara, et al.
Publicado: (2023)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Hee Sung, et al.
Publicado: (2011)

Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors
por: Barrea, Luigi, et al.
Publicado: (2021)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors
por: Cai, Yibo, et al.
Publicado: (2022)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
por: Hu, Yuheng, et al.
Publicado: (2021)

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
por: Bianchi, Antonio, et al.
Publicado: (2013)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
por: Jalbert, Jessica J., et al.
Publicado: (2020)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
por: Campolo, Federica, et al.
Publicado: (2023)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fpp3tn84ek40o2bbcno7he9cfs